Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 2 clients • 9 examiners • 7 art units • 0 of 9 (0%) have an AI response strategy ready
Cepeda Patent Law, LLC. has 9 pending office actions in Biotechnology & Pharmaceuticals and 34 career applications. The pending docket is accompanied by a limited application record, so the available figures describe a focused practice profile rather than a broad historical portfolio.
The resolved allowance rate is 26.67%, and the average is 6.0 office actions per allowance. These measures indicate that resolved outcomes in the record involve substantial examination activity and that allowance has occurred in a minority of resolved matters. Practitioners should examine claim histories and prosecution objectives closely when assessing fit for a biotechnology or pharmaceutical matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| VAN DRUFF, SYDNEY | 1 | 55.3% | +32.0% |
| GURLEY, JAMI MICHELLE | 1 | 54.8% | +14.3% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17058390 | PRODRUGS OF FULVESTRANT | MOORE, SUSANNA | 27d |
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
| 18687882 | METHOD TO OBTAIN A PURIFIED ANTIBODY COMPOSITION | MEAH, MOHAMMAD Y | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | GURLEY, JAMI MICHELLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Dr. Reddy's | 6 |
| KASHIV BIOSCIENCES, LLC | 3 |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1647 | 2 |
| 1615 | 1 |
| 1652 | 1 |
| 1644 | 1 |
| 1643 | 1 |
| 1654 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | DR. REDDY'S LABORATORIES LIMITED | BAZARGANI, ARYA AHMADI | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | Kashiv Biosciences, LLC | WILLIS, DOUGLAS M | 1624 | §112DP | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18687882 | METHOD TO OBTAIN A PURIFIED ANTIBODY COMPOSITION | DR. REDDY'S LABORATORIES LIMITED | MEAH, MOHAMMAD Y | 1652 | §103 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DR. REDDY'S LABORATORIES LIMITED | DRISCOLL, MAUREEN VARINA | 1644 | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | DR. REDDY'S LABORATORIES LIMITED | LANDSMAN, ROBERT S | 1647 | §102§112DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | DR. REDDY'S LABORATORIES LIMITED | VAN DRUFF, SYDNEY | 1643 | §102§103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | DR. REDDY'S LABORATORIES LIMITED | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | Kashiv Biosciences, LLC | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17058390 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 27d | Pending | Nov 24, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial26.7% of resolved applications prosecuted by Cepeda Patent Law, Llc. were allowed, across 34 applications in USPTO records.
6.00 office actions per allowed application on average.
9 pending office actions as of October 2026, for 2 clients, before 9 examiners in 7 art units.
